Respironics aims at total patient ventilation management
This article was originally published in Clinica
Executive Summary
Respironics has formed an agreement to buy Novametrix Medical Systems in a stock swap transaction valued at $8.65 per share. The deal is valued at $90 million, based on the assumption of around $6 million in debt and Respironics' closing price of $34.59.